AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
Interim analysis showed vaccine is effective at preventing COVID-19, with no severe cases and no hospitalisations more than 21 days after first injection Regulatory submissions underway to support approvalResults of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet 32661-1)today, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation. The interim analysis